BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11523406)

  • 1. [Induction of co-stimulatory molecules on the surface of blast cells in patients with acute myeloid leukemia].
    Sadovnikova EIu; Strel'nikova TB; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2001; 73(7):34-40. PubMed ID: 11523406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia.
    Westers TM; Stam AG; Scheper RJ; Regelink JC; Nieuwint AW; Schuurhuis GJ; van de Loosdrecht AA; Ossenkoppele GJ
    Cancer Immunol Immunother; 2003 Jan; 52(1):17-27. PubMed ID: 12536236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The induction of the antitumor activity of T-lymphocytes by antigen-presenting cells obtained from the blast cells of patients with acute leukemias].
    Savchenko VG; Sadovnikova EIu; Parovichnikova EN; Mendeleeva LP; Demidova IA; Sokolov AN; Isaev VG
    Ter Arkh; 2000; 72(7):14-21. PubMed ID: 10983315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adhesion capacity and integrin expression by dendritic-like cells generated from acute myeloid leukemia blasts by calcium ionophore treatment.
    Sadovnikova E; Parovichnikova EN; Semikina EL; Kopiltsova EA; Svinareva DA; Belkin VM; Torubarova NA; Savchenko VG
    Exp Hematol; 2004 Jun; 32(6):563-70. PubMed ID: 15183897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation.
    Houtenbos I; Westers TM; Stam AG; de Gruijl TD; Scheper RJ; Ossenkoppele GJ; van de Loosdrecht AA
    Cancer Immunol Immunother; 2003 Jul; 52(7):455-62. PubMed ID: 12690520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells.
    Vereecque R; Saudemont A; Depil S; Corm S; Andrieux J; Soenen-Cornu V; Quesnel B
    Cancer Immunol Immunother; 2004 Sep; 53(9):793-8. PubMed ID: 15098140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
    Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
    Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
    Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
    Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.
    Kitawaki T; Kadowaki N; Fukunaga K; Kasai Y; Maekawa T; Ohmori K; Itoh T; Shimizu A; Kuzushima K; Kondo T; Ishikawa T; Uchiyama T
    Exp Hematol; 2011 Apr; 39(4):424-433.e2. PubMed ID: 21216276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The immunophenotypic and cytogenetic characteristics of the blast cells in subvariants of acute myeloid leukemia].
    Isakova LM; Tretiak NN; Khromiak VN; Gordienko AI; Zverkova AS; Vakul'chuk AM
    Tsitol Genet; 2000; 34(1):48-56. PubMed ID: 10808542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
    Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
    Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
    Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH
    Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.